Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study

BACKGROUND: Cigarette smoking is the leading preventable cause of premature death. Despite dedicated programmes, quit rates remain low due to barriers such as nicotine withdrawal syndrome or post-cessation weight gain. Glucagon-like peptide-1 (GLP-1) analogues reduce energy intake and body weight an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lengsfeld, Sophia, Burkard, Thilo, Meienberg, Andrea, Jeanloz, Nica, Coynel, David, Vogt, Deborah R., Hemkens, Lars G., Speich, Benjamin, Zanchi, Davide, Erlanger, Tobias E., Christ-Crain, Mirjam, Winzeler, Bettina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120253/
https://www.ncbi.nlm.nih.gov/pubmed/37081574
http://dx.doi.org/10.1186/s13063-023-07164-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120253/
https://www.ncbi.nlm.nih.gov/pubmed/37081574
http://dx.doi.org/10.1186/s13063-023-07164-9

Ejemplares similares